CG ONCOLOGY INC (CGON) Stock News
NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD
CGON Latest News, Press Relases and Analysis
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares...
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CG Oncology Announces Pricing of Public Offering
CG Oncology Announces Pricing of Public Offering
CG Oncology Announces Pricing of Public Offering...
Why CG Oncology (CGON) Stock Is Down 9%
CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock.
CG Oncology Announces Proposed Public Offering
CG Oncology Announces Proposed Public Offering
CG Oncology Announces Proposed Public Offering...
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award...
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips CG Oncology (NASDAQ:CGON) just reported results for the second quarter of 2024....
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
CGON stock results show that CG Oncology beat analyst estimates for earnings per share the second quarter of 2024.
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle...
CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024
CGON stock results show that CG Oncology missed analyst estimates for earnings per share the first quarter of 2024.
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress Posters
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates...
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference...
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates...
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec...
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
- First Patient Dosed in Expanded Access Program and Enrollment Ongoing -
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab...
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab...
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 study